54 Participants Needed

Bempedoic Acid for High Cholesterol in Children

(CLEAR Path 1 Trial)

Recruiting at 27 trial locations
EM
Overseen ByEsperion Medical Information
Age: < 18
Sex: Any
Trial Phase: Phase 2
Sponsor: Esperion Therapeutics, Inc.
Must be taking: Statins
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial
Approved in 2 JurisdictionsThis treatment is already approved in other countries

Trial Summary

What is the purpose of this trial?

Multiple-dose study to measure pharmacokinetics, pharmacodynamics and safety of bempedoic acid in pediatric participants 6 to 17 years of age with HeFH.

Will I have to stop taking my current medications?

Participants must continue taking their current stable lipid-modifying therapy (like statins) at the same dose throughout the trial.

What data supports the effectiveness of the drug Bempedoic acid for high cholesterol in children?

Bempedoic acid has been shown to effectively lower cholesterol levels in adults, particularly in those with familial hypercholesterolemia (a genetic condition causing high cholesterol) and those who cannot tolerate statins. It works by reducing cholesterol production in the liver, and studies have demonstrated its safety and efficacy in lowering LDL cholesterol (the 'bad' cholesterol) in these populations.12345

Is bempedoic acid safe for humans?

Bempedoic acid has been shown to be safe in several studies for lowering cholesterol, with a reduced risk of muscle-related side effects compared to some other treatments. It is approved for use in the USA and EU, and studies have not shown an increase in side effects when combined with other cholesterol-lowering drugs.12346

How is the drug bempedoic acid different from other treatments for high cholesterol?

Bempedoic acid is unique because it lowers cholesterol by targeting the liver specifically, which reduces the risk of muscle-related side effects that are common with other cholesterol-lowering drugs like statins.12347

Research Team

ML

Michael Louie, MD

Principal Investigator

Esperion Therapeutics, Inc.

JC

Jeffrey C Hanselman, MS

Principal Investigator

Esperion Therapeutics, Inc.

Eligibility Criteria

This trial is for children aged 6-17 with HeFH (a genetic cholesterol disorder) who have high LDL cholesterol levels despite taking other lipid-modifying medications. They must not have diabetes, extremely high triglycerides, or be pregnant or breastfeeding.

Inclusion Criteria

Your "bad" cholesterol (LDL-C) level is higher than 130 mg/dL after not eating for a while.
I am between 6 and 17 years old.
I am on a stable treatment for my cholesterol.
See 2 more

Exclusion Criteria

I have diabetes or my blood sugar levels are higher than normal.
Your fasting triglyceride level is 400 mg/dL (4.5 mmol/L) or higher.
I am currently pregnant or breastfeeding.
See 1 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive bempedoic acid once daily with dose adjustments based on body weight for a total of 16 weeks

16 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • Bempedoic acid
Trial OverviewThe study tests the effects of bempedoic acid, a medication intended to lower cholesterol levels in pediatric patients with HeFH. It's given once daily and researchers will monitor how it's processed by the body and its impact on cholesterol.
Participant Groups
3Treatment groups
Experimental Treatment
Group I: Cohort 3Experimental Treatment1 Intervention
Participants at greater than 60 kg body weight at screening receiving once daily 180 mg bempedoic acid for 8 weeks.
Group II: Cohort 2Experimental Treatment1 Intervention
Participants at 30 to 60 kg body weight at screening receiving once daily120 mg bempedoic acid for 8 weeks followed by 150 mg bempedoic acid for 8 weeks.
Group III: Cohort 1Experimental Treatment1 Intervention
Participants at 16 to \<30 kilograms (kg) body weight at screening receiving once daily 60 milligrams (mg) bempedoic acid for 8 weeks followed by 90 mg bempedoic acid for 8 weeks.

Bempedoic acid is already approved in United States, European Union for the following indications:

🇺🇸
Approved in United States as Nexletol for:
  • Hypercholesterolemia in combination with diet and the highest tolerated statin therapy in adults with heterozygous familial hypercholesterolemia, or with established atherosclerotic cardiovascular disease, who need additional lowering of LDL cholesterol
🇪🇺
Approved in European Union as Nilemdo for:
  • Primary hypercholesterolaemia (heterozygous familial and non familial) or mixed dyslipidaemia, as an adjunct to diet in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin; or alone or in combination with other lipid-lowering therapies in patients who are statin intolerant, or for whom a statin is contraindicated

Find a Clinic Near You

Who Is Running the Clinical Trial?

Esperion Therapeutics, Inc.

Lead Sponsor

Trials
26
Recruited
21,900+
Founded
2008
Headquarters
Ann Arbor, USA
Known For
Cholesterol Therapies
Top Products
NEXLETOL, NEXLIZET, NILEMDO, NUSTENDI

Findings from Research

Bempedoic acid has been approved in the USA and EU for treating high cholesterol, based on positive results from the phase III CLEAR clinical trial program.
It is available both as a standalone treatment (NEXLETOL® in the USA, Nilemdo® in the EU) and in combination with ezetimibe (NEXLIZET® in the USA, Nustendi® in the EU), highlighting its versatility in managing hypercholesterolaemia.
Bempedoic Acid: First Approval.Markham, A.[2022]
Bempedoic acid has been approved as a new treatment for hypercholesterolemia, showing both efficacy and safety in clinical studies, making it a valuable option for managing cholesterol levels.
Unlike statins, bempedoic acid selectively targets the liver, which lowers the risk of muscle-related side effects, providing a safer alternative for patients who may be sensitive to traditional cholesterol-lowering medications.
[ANMCO Expert opinion: Bempedoic acid place in therapy for hypercholesterolemia management].Di Fusco, SA., Aquilani, S., Spinelli, A., et al.[2023]
Bempedoic acid significantly lowers various cholesterol levels, including total cholesterol and low-density lipoprotein (LDL) cholesterol, with a large study involving 3,788 participants across 10 randomized controlled trials.
While bempedoic acid has a favorable effect on lipid profiles, it is associated with some risks, such as elevated liver enzymes and uric acid levels, but it may reduce the risk of new or worsening diabetes.
Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: A systematic review and meta-analysis.Cicero, AFG., Fogacci, F., Hernandez, AV., et al.[2020]

References

Bempedoic Acid: First Approval. [2022]
[ANMCO Expert opinion: Bempedoic acid place in therapy for hypercholesterolemia management]. [2023]
Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: A systematic review and meta-analysis. [2020]
[Opportunities and perspectives for bempedoic acid use in clinical practice]. [2021]
Bempedoic Acid for Heterozygous Familial Hypercholesterolemia: From Bench to Bedside. [2021]
Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance. [2021]
Effect of Bempedoic Acid on atherogenic lipids and inflammation: A meta-analysis. [2021]